Daxor Corporation (DXR)
NASDAQ: DXR · Real-Time Price · USD
8.08
+0.06 (0.69%)
Mar 31, 2025, 11:10 AM EDT - Market open
Daxor Revenue
In the year 2024, Daxor had annual revenue of $119.71K, down -26.75%. Daxor had revenue of $47.96K in the half year ending December 31, 2024, a decrease of -50.25%.
Revenue (ttm)
$119.71K
Revenue Growth
-26.75%
P/S Ratio
332.82
Revenue / Employee
$3,236
Employees
37
Market Cap
39.84M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 119.71K | -43.71K | -26.75% |
| Dec 31, 2023 | 163.42K | -68.22K | -29.45% |
| Dec 31, 2022 | 231.64K | -46.45K | -16.70% |
| Dec 31, 2021 | 278.09K | 13.65K | 5.16% |
| Dec 31, 2020 | 264.44K | -115.70K | -30.44% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
DXR News
- 3 days ago - Daxor Expands Blood Volume Analysis Technology Across Midwest, Wisconsin, and New Jersey Healthcare Networks - GlobeNewsWire
- 24 days ago - Daxor Corporation (DXR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024 - GlobeNewsWire
- 26 days ago - Daxor Corporation to Host Investor Conference Call to Discuss Fiscal Year 2024 Financial Results and Provide a Corporate Update on March 6, 2025 - GlobeNewsWire
- 27 days ago - Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders - GlobeNewsWire
- 27 days ago - Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 - GlobeNewsWire
- 4 weeks ago - Daxor Expands Blood Volume Analysis Services at Major Midwest Healthcare Center - GlobeNewsWire
- 4 weeks ago - Daxor Corporation Expands Blood Volume Analysis Technology to Major New Jersey Hospitals - GlobeNewsWire